Efficacy of viral load suppression on life expectancy of human immunodeficiency virus patients: a literature review

Authors

  • Moses Bwambale Kyamakya Division of Monitoring, Evaluation and Quality Assurance, Mildmay, Kampala, Uganda
  • Vikram Niranjan Health Research Institute, Graduate entry medical School, University of Limerick, Limerick, Ireland

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20195882

Keywords:

Efficacy, HIV/AIDS, Life expectancy, Viral load

Abstract

In a bid mitigate the spread of HIV and AIDS since it was diagnosed, several interventions ranging from palliative care, increased access to HIV treatment to manage opportunistic infections and the current drive of improving clinical outcomes through suppression of viral load are all aimed at prolonging survival of HIV and AIDS patients. The authors endeavour to corroborate the effect of viral load (VL) suppression on ART HIV patients. The authors applied a comprehensive search by merging terms for survival of HIV patients to clinical, demographic and socio-economic factors in NCBI and MEDLINE databases. About 15 articles were considered by outlining research questions, generating key words and search terminologies. Only articles published since 2013 during scale up of VL interventions were considered. It is worth noting that unsuppressed VL clinically decisively causes death in HIV/AIDS patients, propelled by a number of associated causes including opportunistic infections (OIs) Tuberculosis (TB), Non communicable diseases (NCDs), age, sex, income, geographic location among others. Whereas there is marked decline in risk of dying among HIV/AIDS patients resulting from VL suppression, other factors including; early detection and timely treatment, managing OIs, NCDs and TB treatment, tackling socio-economic barriers and multi-pronged community focused interventions like Community Client Led ART Delivery CCLAD, Community Drug Distribution Point (CDDP) interventions enhance survival of HIV/AIDS patients on lifelong ART.

References

Ford N, Meintjes G, Vitoria M, Greene G, Chiller, T. The evolving role of CD4 cell counts in HIV care. Current Opinion HIV AIDS. 2017;12(2):123-8.

Trickey A, May MT, Vehreschild JJ, Obel N, Gill MJ, Crane HM, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV. 2017;4(8):e349-56.

Saraceni V, Durovni B, Cavalcante SC, Cohn S, Pacheco AG, Moulton LH, et al. Survival of HIV patients with tuberculosis started on simultaneous or deferred HAART in the THRio cohort, Rio de Janeiro, Brazil. The Brazilian J Infect Dis. 2014;18(5):491-5.

Gamboa-Acuña B, Guillén-Zambrano R, Lizzetti-Mendoza G, Soto A, Lucchetti-Rodríguez A. Factors associated with survival in patients with HIV-TB co-infection in the Infectious Disease Service of the Arzobispo Loayza National Hospital, Peru, during the years 2004-2012. Revista Chilena De Infectología. 2018;35(1):41-8.

Arpadi SM, Shiau S, Gusmao EPD, Violari A. Routine viral load monitoring in HIV-infected infants and children in low- and middle-income countries: challenges and opportunities. Journal of the International AIDS Society, 2017;20:e25001.

Jose S, Delpech V, Howarth A, Burns F, Hill T, Porter K. A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. The Lancet HIV. 2018;5(6):e301-8.

Coninck ZD, Hussain-Alkhateeb L, Bratt G, Ekström AM, Gisslén M, Petzold M, et al. Non-AIDS mortality is higher among successfully treated people living with HIV compared with matched HIV-negative control persons: A 15-year follow-up cohort study in Sweden. AIDS Patient Care and STDs. 2018;32(8):297-305.

Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 2016. Available at: https://www.who.int/hiv/pub/ arv/arv-2016/en/. Accessed 10 October 2019.

Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. The Lancet HIV, 2015;2(10):e438-44.

Musheke M, Bond V, Merten S. Self-care practices and experiences of people living with HIV not receiving antiretroviral therapy in an urban community of Lusaka, Zambia: implications for HIV treatment programmes. AIDS Research and Therapy. 2013;10(1):12.

Hentzien M, Cabie A, Pugliese P, Billaud É, Poizot-Martin I, Duvivier C. Factors associated with deaths from suicide in a French nationwide HIV-infected cohort. HIV Med. 2015;19(8):551-8.

Currier JS, Hsue PY. The role of inflammation in HIV-associated atherosclerosis-one size may not fit all. J Infect Dis. 2019; In press.

Agolory S, Klerk MD, Baughman AL, Sawadogo S, Mutenda N, Pentikainen N, et al. Low case finding among men and poor viral load suppression among adolescents are impeding namibia’s ability to achieve UNAIDS 90-90-90 Targets. Open Forum Infect Dis. 2018;5(9):ofy200.

Fast-Track: ending the AIDS epidemic by 2030, 2014. Available at: https://www.unaids.org/sites/ default/files/media_asset/JC2686_WAD2014report_ en.pdf. Accessed 10 October 2019.

Kim AA, Mukui I, N’Gan’Ga L, Katana A, Koros D, Wamicwe J, et al. Progress in Reversing the HIV Epidemic through Intensified Access to Antiretroviral Therapy: Results from a Nationally Representative Population-Based Survey in Kenya, 2012. Plos One. 2016;11(3):e0148068.

Downloads

Published

2019-12-25

How to Cite

Kyamakya, M. B., & Niranjan, V. (2019). Efficacy of viral load suppression on life expectancy of human immunodeficiency virus patients: a literature review. International Journal Of Community Medicine And Public Health, 7(1), 361–366. https://doi.org/10.18203/2394-6040.ijcmph20195882

Issue

Section

Review Articles